Kinases

The role of KDR in the survival of HTLV-1-infected T cells

23 July 2024 | By Drug Target Review

KDR inhibitors could be very impactful for treatment of ATLL and HAM/TSP or prevent disease by lessening the viral load of HTLV-1.

Finding the fundamental pathway in ALD pathogenesis

17 January 2024 | By Drug Target Review

Liver-specific knockdown of TRPC3 enhanced alcohol's inhibitory effect on AMPK through a mechanism of Ca2+-dependent CaMKK2 activation.

Enzyme substrate mutations promote tumour growth

5 July 2023 | By Izzy Wood (Drug Target Review)

Using a newly developed algorithm and a validation study, US researchers find that cancer hijacks a class of enzyme mutations to fuel tumorigenesis.

Researchers discover clues on how cells control their volume

1 November 2022 | By Ria Kakkad (Drug Target Review)

A new study from the University of Pittsburgh and Carnegie Mellon University may solve the puzzle of how cells control their volume.

Study reveals how molecular motor proteins are involved in malaria transmission

29 July 2022 | By Ria Kakkad (Drug Target Review)

Scientists have made a breakthrough in how malaria parasites divide and transmit the disease, a major step forward in preventing one of the biggest killer infections in the world.

New research sheds light on what influences target protein binding time

3 February 2022 | By Mandy Parrett (Drug Target Review)

The length of time that drug molecules attach to their target protein varies greatly and impacts the protein’s behaviour and drug efficacy. In a new study, scientists in Finland have identified some causal factors for this variance, with the hope it will bring clarity for drug developers.

Automating functional cell-based bioassays: assay reproducibility and performance for potency testing programmes

28 May 2021 | By Eurofins DiscoverX* and Tecan

In this on-demand webinar, we discuss how Eurofins DiscoverX’s off-the-shelf, MOA-based functional, cellular assays address these challenges, enabling drug discovery programmes up to late-stage development and market release.

Catalogue: Drug target reagents

20 April 2021 | By Sino Biological Inc.

5,000+ drug target reagents for antibody, small molecule drug discovery and development, including immune checkpoints, cytokines and kinases.

Novel small molecule inhibitors of oncogenic SHP2 variants characterised by cellular target engagement

28 January 2021 | By Eurofins DiscoverX & Sanford Burnham Prebys Discovery

In this on-demand webinar industry experts discuss how the InCELL Pulse technology provides a valuable tool for the discovery and characterisation of novel SHP2 inhibitors.

BellBrook Labs

Apilimod small molecule shows potent inhibition of SARS-CoV-2 in cells

7 August 2020 | By Victoria Rees (Drug Target Review)

Researchers have found the small molecules Apilimod and Vacuolin-1 inhibited the PIKfyve kinase in cells, preventing infection from Zaire ebolavirus and SARS-CoV-2.

Application note: A kinase inhibitor phenotypic screen using a multiplex T Cell activation assay

22 June 2020 | By IntelliCyt Corporation

Modulating the TCR signaling pathway using biologics, small molecules or genetic engineering is highly relevant to many therapeutic areas including cancer immunotherapy, adoptive cell therapy, vaccine development and autoimmune disease.

Binding site of drug compound and tumour suppressor protein revealed

21 April 2020 | By Victoria Rees (Drug Target Review)

Using cyro-electron microscopy, researchers have imaged the binding site between a molecule and the tumour suppressor protein PP2A, enabling optimisation of the drug compound.

Targeted protein degradation: the next wave of therapeutics

23 March 2020 | By Victoria Rees (Drug Target Review)

Using the ubiquitin-proteasome system to fight inflammatory conditions could provide more treatment options for patients. Dr Jared Gollob from Kymera Therapeutics explains why targeted protein degradation is the way forward for autoinflammatory and autoimmune disease therapies.

Researchers gain new insight into LRRK2 – a potential cause of Parkinson’s

20 February 2020 | By Mandy Parrett (Drug Target Review)

Scientists in the US have applied a novel technique to finally unravel a particular kinase enzyme that is associated with familial Parkinson’s disease; providing a clearer potential therapeutic target.